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Abstract 39 
Whilst obesity is a key predisposing risk factor in the development of insulin resistance and 40 
type 2 diabetes mellitus, not all obese subjects develop insulin resistance. This study aimed to 41 
identify key anthropometric and biochemical parameters that predict insulin sensitivity in 42 
overweight and obese adults. Based on previous literature, we hypothesised that markers of 43 
insulin sensitivity would be negatively correlated with plasma concentrations of free fatty 44 
acids (FFA) and liver enzymes. Forty non-diabetic adult subjects (body mass index (BMI) ≥ 45 
25.0kg/m2) were recruited. Data collection included anthropometric measurements and 46 
fasting plasma samples for the quantification of liver enzymes (ALT, AST, GGT), blood lipid 47 
profile and markers of insulin sensitivity. Questionnaires relating to dietary intake, physical 48 
activity and fatigue were also completed. Insulin and Homeostasis Model of Assessment 49 
(HOMA) scores were significantly correlated with indirect measures of central obesity 50 
(P<0.05). Glycosylated haemoglobin, insulin and HOMA scores for Insulin Resistance (IR) 51 
were all positively correlated with selected liver function markers (P<0.05). HOMA-IR 52 
scores were significantly positively correlated with and plasma phospholipid levels of n-3 53 
fatty acids (P=0.04) and n-3:n-6 ratio (P<0.05) and negatively correlated with n-6 fatty acids 54 
(P=0.03). No significant correlations were found between markers of insulin sensitivity and 55 
cholesterol levels, physical activity or self-reported fatigue. These results have reinforced the 56 
integral role of liver function in development of insulin resistance. Despite previous data 57 
linking elevations in FFA to the development of insulin resistance, we found no relationship 58 
between these variables in this study. 59 
Keywords: human, obesity, insulin, liver, n-3 fatty acids, n-6 fatty acids. 60 
61 
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1. Introduction 62 
Obesity is thought to have a causal effect on the development of skeletal muscle insulin 63 
resistance and the subsequent development of type 2 diabetes mellitus (T2DM)[1]. Central 64 
adiposity is one of the key risk factors for the development of insulin resistance and 65 
progression towards T2DM and forms the basis of the portal/visceral hypothesis for the 66 
development of insulin resistance[2]. According to this hypothesis, increased adiposity 67 
(specifically visceral adiposity), leads to greater movement of free fatty acids (FFA) and 68 
inhibition of insulin action via Randle's effect in insulin-sensitive tissues[3]. Thus, the 69 
presence of an increased supply of FFA reduces muscle glucose utilisation, leading to 70 
reduced glucose clearance in the periphery and enhancing insulin secretion. In addition, the 71 
prolonged lipotoxic effect of these fatty acids on the pancreatic β-cells is posited to link 72 
obesity, insulin resistance and development of T2DM[4]. With recent literature questioning 73 
the validity of this hypothesis, alternative theories including the ectopic fat storage 74 
syndrome[5] and the endocrine paradigm[6] have been proposed. Prior to the onset of 75 
diabetes, insulin resistant individuals are able to compensate for increases in blood glucose by 76 
increased insulin secretion by pancreatic β cells. T2DM develops when this process is no 77 
longer sufficient to maintain normal fasting levels of blood glucose[7]. 78 
Healthy diet and regular physical activity can prevent or delay the onset of T2DM[8]. Whilst 79 
lipids have a greater energy density per gram than carbohydrates or proteins, selective intake 80 
of specific fatty acids, in particular the n-3 and n-6 polyunsaturated fatty acids (PUFA), can 81 
differentially impact upon satiety and adiposity through their influence on adipokine 82 
production[9, 10]. Both the n-3 and n-6 PUFA are essential fatty acids, that is, they must be 83 
obtained from dietary or supplementary sources[11]. While intakes of sufficient quantities of 84 
both n-3 and n-6 PUFA is necessary for the maintenance of optimal health[11], it also 85 
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appears that n-3 and n-6 PUFA have distinct biological actions in relation to metabolic 86 
health.  87 
Previous studies have reported that increased n-3 PUFA status is associated with a lower 88 
body mass index (BMI) and waist circumference (WC), suggesting that the n-3 fatty acids 89 
may be protective against weight gain, abdominal obesity[12] and the effects of non-90 
alcoholic fatty liver disease[13]. Similarly, n-3 fatty acids stimulate production of the insulin-91 
sensitising hormone, adiponectin, which would be expected to have a positive effect on 92 
insulin sensitivity[14].  In contrast, there have been no reports linking increased n-6 PUFA 93 
intake with markers of metabolic health. Enhanced n-6:n-3 ratios are believed to result in a 94 
pro-inflammatory state[15], favouring the development metabolic syndrome and associated 95 
conditions such as non-alcoholic fatty liver disease[16].  96 
Increased fatigue levels have also been correlated positively with percentage body fat[17] and 97 
obesity[18-20]. Further, self-reported fatigue is negatively associated with the likelihood of 98 
getting recommended levels of physical activity[21]. Thus, obesity-associated increases in 99 
fatigue are hypothesised to play an integral role in poor weight management, and restricted 100 
physical activity levels[20]. This has further ramifications for self-esteem and eventually the 101 
health system, work force and the economy[22] making primary prevention of obesity and 102 
subsequent fatigue a necessity.  103 
Whilst obesity remains a key predisposing risk factor in the development of insulin 104 
resistance, the reasons why not all obese subjects progress to develop insulin resistance 105 
remain unclear. Based on previous literature, we hypothesised that markers of insulin 106 
sensitivity would be positively correlated with plasma FFA levels and liver enzymes and 107 
negatively correlated to plasma levels of n-3 PUFA and the n-3:n-6 PUFA ratio. This study 108 
aims to identify key anthropometric and biochemical parameters that predict insulin 109 
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sensitivity in overweight and obese adults with potential implications for the future 110 
identification of at risk individuals and future weight management strategies. With a focus on 111 
identifying parameters that may indicate increased risk of insulin sensitivity within the 112 
general population, consideration must be given to both male and female participants from 113 
broad age range. 114 
2. Methods 115 
2.1 Subjects 116 
Forty subjects were recruited from within the greater Brisbane area for a study assessing the 117 
effects of n-3 fatty acid supplementation on adipokine levels. Equal proportions of males and 118 
females were recruited, with a total of 10 overweight (5 males, 5 females) and 30 obese 119 
subjects (15 males, 15 females) , between 18 and 80 years of age. Study criteria required that 120 
subjects have a BMI ≥25.0 kg/m2. Exclusion criteria included previous diagnosis with type 1 121 
or type 2 diabetes mellitus, weight loss of more than 10% body weight within the last six 122 
months, active substance abuse (alcohol or drug dependency), smoking, breast feeding or 123 
pregnancy, concomitant use cholesterol medications or nutritional supplements.  Written 124 
informed consent was obtained from all subjects.  125 
2.2 Study Design 126 
Upon recruitment, subjects’ anthropometric measures were taken and fasting blood samples 127 
collected. Anthropometric measures included height, weight, WC and hip circumference. WC 128 
was measured to the nearest 0.1 cm at the umbilicus level. Hip circumference was measured 129 
to the nearest 0.1cm at the widest point between the iliac crest and buttock. BMI was 130 
calculated as weight in kilograms divided by the square of the height in meters, squared 131 
(kg/m2). BMI groups were based on World Health Organisation classifications for adults[23]. 132 
An overweight BMI range was categorised as 25.0 kg/m2 ≤ BMI > 30.0 kg/m2 and a 133 
7  
Predictors of Insulin Sensitivity 
BMI≥30.0 kg/m2 was classified as obese. Fasting blood samples were utilised for the 134 
quantification of adipose hormones (total adiponectin and leptin), markers of insulin 135 
sensitivity, electrolyte and liver function, cholesterol, FFA and plasma phospholipid fatty 136 
acids. Homeostasis Model of Assessment (HOMA) scores for Insulin Resistance (IR) and 137 
pancreatic beta cell function () were calculated based on fasting glucose and insulin levels 138 
(HOMA-IR = (fasting plasma insulin x fasting plasma glucose)/22.5; HOMA- = (20 x 139 
fasting plasma insulin)/(fasting plasma glucose- 3.5))[24]. It was not possible to carry out all 140 
analyses in every individual due to the inability to collect a sufficient volume of blood from 141 
some individual participants to conduct every assay. In this case a subset of the analyses were 142 
performed for this participant. 143 
Each subject also completed a validated 72hour dietary recall[25] and International Physical 144 
Activity Questionnaires (IPAQ)[26-28] at this time. Dietary records were analysed in 145 
Foodworks to determine the mean reported energy intake for each subject (2007; Xyris 146 
Software, Brisbane, Australia). Self-reported fatigue was measured using the Fatigue Impact 147 
Scale (FISK) which examines patient perceptions of the functional limitations imposed by 148 
fatigue on cognitive, physical, and psychosocial functioning[29].  149 
The study design was approved by Metro South Human Research Ethics Committee 150 
(HREC/10/QPAH/141) and The University of Queensland Medical Research Ethics 151 
Committee (2010001200). 152 
2.4 Assays 153 
Adiponectin and and intercellular adhesion molecule 1 (ICAM-1) were measured by Cardinal 154 
Bioresearch, Brisbane, utilising Multiplex ELISA techniques on a Luminex platform. These 155 
assays were performed with Human Adiponectin/Acrp30[30] and Human ICAM-1/CD54 156 
Biotinylated Affinity Purified PAb antibodies[31] supplied by R&D Systems, following the 157 
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standard procedures outlined in the corresponding Human Obesity MultiAnalyte Profiling 158 
Base Kit[32]. Acylated ghrelin was measured utilising Millipore Human Ghrelin (active) 159 
ELISA kits supplied by Abacus ALS, Australia[33]. FFA were measured using a NEFA 160 
assay from Wako Diagnostics in Osaka, Japan[34]. Plasma phospholipid fatty acid 161 
concentrations were measured by gas chromatography in conjunction with FOODplus 162 
Research Centre at The University of Adelaide[14]. All other pathological markers were 163 
analysed by Pathology Queensland (Princess Alexandra Hospital, Brisbane). 164 
2.5 Statistical Analyses 165 
All data are expressed as means ± standard deviation. Differences between overweight and 166 
obese groups for each parameter were assessed using standard t-tests. Relationships between 167 
variables were assessed by nonparametric correlation analysis (Spearman’s rank correlation 168 
coefficient). P values <0.05 were considered of statistical significance. All statistical analyses 169 
were performed in SPSS version 20.0. 170 
3. Results 171 
Mean and standard deviation data for anthropometric measures, markers of insulin sensitivity 172 
and selected metabolic parameters are summarised for overweight and obese participants in 173 
Table 1. Subjects were aged between 23 and 79 years with a mean BMI of 32.8kg/m2. 174 
Indirect measures of adipose tissue distribution including WC, waist:height ratio (WHtR) and 175 
waist:hip ratio (WHpR) were higher in obese than overweight subjects. There were no 176 
significant differences between overweight and obese groups in relation to plasma levels of 177 
glucose (P=0.22), insulin (P=0.49), HbA1C (National Glycohemoglobin Standardization 178 
Program (NGSP); P=0.20) or HOMA-IR (P=0.97).  179 
Mean reported energy intake for the subjects was 4246 ± 1930 kJ. No significant difference 180 
was observed between the mean energy intake of overweight and obese subjects (P=0.57). 181 
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Mean self-reported physical activity level across all subjects was 4585.2 ±6517.3 MET-182 
minutes/week. Mean total self-reported fatigue scores as determined by FISK Questionnaires 183 
was 32.0 ± 29.2, on a scale of 0 (No Problem) to 160 (Extreme Problem). No significant 184 
difference in physical activity (as measured by IPAQ) or fatigue scores were observed 185 
between overweight and obese subjects (P=0.91 and P=0.44 respectively). 186 
Spearman’s correlation coefficients (r) and coefficients of variation (CV) for plasma glucose 187 
concentrations are shown in Table 2. There were no statistically significant correlations 188 
observed between plasma glucose levels and anthropometric parameters including BMI or 189 
waist circumference. Plasma glucose concentrations were positively correlated with plasma 190 
phospholipid proportions of total n-3 PUFA (r=0.40, P=0.01), eicosapentaenoic acid (EPA; 191 
r=0.48, P<0.01), docosaexaenoic acid (DHA; r=0.33, P=0.04) and the n-3:n-6 ratio (r=0.40, 192 
P=0.01). Conversely, glucose levels were inversely correlated with n-6 fatty acid content of 193 
plasma phospholipids (r=-0.33, P=0.04). Other biochemical markers associated with glucose 194 
included calcium (inverse relationship; r=-0.37, P=0.02) and acylated ghrelin (positive 195 
relationship; r=0.34, P=0.04).  196 
Spearman’s correlation coefficients (r) and coefficients of variation (CV) for plasma insulin 197 
concentrations are also summarised in Table 2. Positive correlations were observed between 198 
insulin and anthropometric measures included waist circumference (r=0.61, P<0.01) and 199 
waist:height ratio (WHtR; r=0.48, P=0.01). Of further interest, insulin was positively 200 
correlated with a number of electrolyte and liver function parameters including alanine 201 
transaminase (ALT; r=0.44, P=0.02), gamma-glutamyl transpeptidase (GGT; r=0.49, P<0.01) 202 
and estimated glomerular filtration rate (eGFR; r=0.56, P=0.02). Correlations between insulin 203 
and other metabolic parameters included an inverse relationship to adiponectin (r=-0.49, 204 
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P<0.01) and positive relationships with ICAM-1 (r=0.49, P<0.01) and plasma phospholipid 205 
percentages of total saturated fatty acids (r=0.56, P<0.01). 206 
Spearman’s correlation coefficients (r) and coefficients of variation (CV) for glycosylated 207 
haemoglobin levels (HbA1c (NGSP)) are also summarised in Table 2. HbA1C (NGSP) was   208 
correlated with a number of liver enzymes including alkaline phosphatase (ALP; r=0.47, 209 
P<0.01), ALT (r=0.44, P<0.01), aspartate transaminase (AST; r=0.42, P<0.01), GGT (r=0.38, 210 
P=0.02) and inversely correlated with eGFR (r=-0.50, P=0.498).  211 
HOMA-IR and HOMA-β scores, derived from calculations pertaining to fasting glucose and 212 
insulin levels, were also assessed for correlations with anthropometric and metabolic 213 
parameters. A summary of the results from Spearman’s correlations of HOMA-IR scores are 214 
shown in Table 3. Significant correlations were observed between HOMA-IR and 215 
anthropometric parameters including BMI (r=0.38, P=0.04), WC (r=0.60, P<0.001) and 216 
WHtR (r=0.50, P<0.01), whilst HOMA-β was only significantly correlated with WC (r=0.41, 217 
P=0.03).Of the electrolyte and liver function parameters, HOMA-IR was significantly 218 
positively correlated with GGT (r=0.39, P=0.04) and eGFR (r=0.57, P=0.02), with inverse 219 
correlations to phosphate (r=-0.39, P=0.04). Conversely, HOMA-β was positively correlated 220 
with ALT (r=0.54, P<0.01), AST(r=0.44, P=0.02) and GGT (r=0.55, P<0.01). No direct 221 
correlations were observed between HOMA-IR and cholesterol, however, HOMA-β was 222 
significantly inversely correlated with LDL cholesterol (r=-0.43, P=0.02).  223 
As with glucose, significant positive correlations were observed between HOMA-IR scores 224 
and selected plasma phospholipid percentages including total saturated fatty acids (r=0.55, 225 
P<0.01), total n-3 fatty acids (r=0.38, P=0.04), EPA (r=0.42, P=0.02) and the n-3:n-6 ratio 226 
(r=0.37, P=0.046), with inverse correlations to total n-6 percentages (r=-0.40, P=0.03). 227 
Conversely, the only significant correlations observed between plasma phospholipids and 228 
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HOMA-β were with the total saturated fatty acid content (r=0.41, P=0.03). Additional 229 
negative correlations were observed between HOMA-IR and adiponectin (r=-0.46, P=0.01), 230 
as well as a positive correlation with ICAM-1 (r=0.43, P=0.02). HOMA-β was negatively 231 
correlated with adiponectin (r=-0.42, P=0.02) and acylated ghrelin (r=-0.38, P=0.0499) yet 232 
positively correlated with ICAM-1 (r=0.43, P=0.02).  233 
No significant correlations were observed between cholesterol measures (total cholesterol, 234 
LDL cholesterol, HDL cholesterol and triglycerides) and markers of insulin sensitivity 235 
including glucose, insulin, HbA1C and HOMA-IR (P≥0.05). No significant correlations were 236 
observed between plasma free fatty acid levels and markers of insulin sensitivity including 237 
glucose (r=-0.18, P=0.27), insulin (r=0.01, P=0.95), HbA1C (NGSP; r=-0.06, P=0.71) and 238 
HOMA-IR (r=-0.08, P=0.69). 239 
Of further interest, self-reported fatigue levels were inversely correlated with plasma 240 
phosphate concentrations (r=-0.33, P=0.04) and positively correlated with C-reactive protein 241 
(r=0.57, P<0.01). Within this cohort, no significant correlations were observed between self-242 
reported fatigue and anthropometric markers, such as BMI (r=0.17, P=0.28), glucose (r=-243 
0.24, P=0.14), HbA1C (NGSP; r=-0.02, P=0.31) or HOMA-IR (r=0.18, P=0.35). 244 
4. Discussion 245 
Obesity is a key pre-disposing risk factor in the development of insulin resistance and T2DM, 246 
however, not all obese subjects develop insulin resistance. This study aimed to identify key 247 
anthropometric and biochemical parameters that predict insulin sensitivity in overweight and 248 
obese adults. 249 
Previous studies suggest that central adiposity is associated with an increased risk of insulin 250 
resistance and T2DM[3]. WC serves as simple, more convenient means of approximating 251 
central obesity[35]. Thus, correlations between markers of insulin sensitivity (insulin and 252 
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HOMA-IR scores) and both WC and WHtR support the association between central adiposity 253 
and insulin resistance within overweight and obese subjects. 254 
The liver plays an integral role in maintaining normal glucose concentrations[36]. Following 255 
the development of hepatic insulin resistance, insulin is no longer able to suppress hepatic 256 
glucose production, resulting in elevated blood glucose concentrations[36]. In cases of 257 
cirrhosis, liver transplantation has been shown to improve whole-body insulin sensitivity, 258 
highlighting the important role of the liver in the regulation of glucose homeostasis[37]. In 259 
the present study, we also found correlations between selected electrolyte and liver function 260 
parameters and markers of insulin sensitivity in overweight and obese subjects. Specifically, 261 
insulin levels were positively correlated with ALT, and HOMA-IR was positively correlated 262 
with GGT. Both HbA1C and HOMA-β were correlated positively with ALT and GGT. These 263 
results are consistent with previous studies suggesting that these two enzymes are important 264 
biomarkers for metabolic syndrome[38, 39], and elevated levels of ALT[40] and GGT[41] 265 
have previously been associated with later development of diabetes. ALT and GGT have 266 
been also been inversely correlated with adiponectin levels. As adiponectin levels are also 267 
inversely correlated with obesity[42], it is plausible that adiponectin may provide a link 268 
between elevations in liver enzymes and hyperinsulinemia in obesity, as well as the 269 
subsequent development of metabolic syndrome. 270 
The importance of adipose tissue in the regulation of metabolic processes including insulin 271 
metabolism was clearly demonstrated through significant inverse correlations between 272 
adiponectin levels and both insulin and HOMA-IR. This is not surprising given that 273 
adiponectin levels decrease as the degree of adiposity increases and this hormone is also 274 
known to promote glucose uptake in the liver and skeletal muscle[43], with low adiponectin 275 
concentrations linked to T2DM[44]. Concurrent correlations were also observed between 276 
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markers of insulin sensitivity (insulin and HOMA-IR scores) and inflammatory molecule 277 
ICAM-1, further supporting previous data pertaining to correlations between inflammation, 278 
adiponectin levels and the subsequent development of insulin resistance[45]. 279 
Ghrelin is a gut-derived hormone which, in addition to its role as a hunger signal, also has an 280 
established role  in the regulation of fat mass and glucose homeostasis[5]. This is supported 281 
by the results of the present study, which identified a significant positive correlation between 282 
acylated ghrelin and both glucose and HOMA-β. 283 
It is clear that the relative proportions of fatty acids incorporated within the phospholipids are 284 
related to these markers of insulin sensitivity, specifically noting inverse correlations between 285 
markers of insulin sensitivity (glucose and HOMA-IR) with n-6 fatty acids and positive 286 
correlations with total n-3 fatty acids, EPA, DHA and the ratio of n-3:n-6 fatty acids.  Given 287 
these correlations, it would therefore be plausible that supplementing with n-3 fatty acids may 288 
result in increased glucose and HOMA-IR scores in obese participants whilst n-6 fatty acids 289 
would have the opposite effect. Results of previous studies have demonstrated insufficient 290 
evidence to suggest impaired glycaemic control associated with use of n-3 in patients with 291 
T2DM, showing no significant changes in fasting glucose, fasting insulin or body weight[46]. 292 
This is of particular interest, given that n-3 has been shown to increase adiponectin levels in 293 
obese subjects[47] and increased adiponectin levels are associated with improvements in 294 
insulin sensitivity[43, 48]. Further research is required in order to fully understand these 295 
apparently conflicting results. 296 
Previous literature suggests that mobilisation of FFA in the circulation also promote insulin 297 
resistance[49]. By contrast, this study found no direct correlations between FFA and markers 298 
of insulin sensitivity. Further, there were no clear correlations between markers of insulin 299 
sensitivity (glucose, insulin, HbA1C or HOMA scores) and physical activity or self-reported 300 
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fatigue. Fatigue scores were correlated with C-Reactive Protein suggesting that inflammation 301 
may play a role, though there was no significant correlation to ICAM-1. Further investigation 302 
is still needed to better understand and treat fatigue in obesity, given the significant 303 
limitations this has on quality of life[50], weight management[20] as well as the ability to 304 
maintain the recommended levels of physical activity in obese subjects[21]. 305 
These results support previous literature regarding the integral role of the liver in the 306 
development of insulin resistance. Significant correlations are observed between markers of 307 
insulin sensitivity and liver enzymes as well as adipose derived hormone adiponectin and 308 
inflammatory marker ICAM-1 suggesting a plausible link between liver function, adiposity 309 
and the development of insulin resistance. Despite previous data linking elevations in FFA to 310 
the development of insulin resistance, there were no significant correlations between these 311 
factors observed in overweight and obese subjects. Thus, authors partially accept the original 312 
hypothesis, noting that markers of insulin sensitivity were positively correlated with liver 313 
enzymes but not plasma FFA levels. 314 
Positive correlations to n-3 fatty acids and markers of insulin sensitivity suggests that 315 
theoretically, caution may be warranted when supplementing obese participants with these 316 
fatty acids though previous literature does not indicate significant adverse clinical 317 
implications related to n-3 intake. Additional correlations observed between markers of 318 
insulin sensitivity and n-6 fatty acids as well as n-3:n-6 ratios provide alternate directions for 319 
future research. 320 
There are limitations inherent within the design and outcomes of any study. Whilst the 321 
sample size of this study was sufficient in meeting the desired aims, future trials 322 
incorporating a larger cohort would allow for additional sub-analyses for variables such as 323 
age and gender. In addition, all subjects were drawn from the same region, it is therefore 324 
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plausible that this population may not be indicative of other geographical locations. In 325 
relation to age, ethnicity and socio-economic status, the characteristics of the subjects 326 
indicate that they were relatively representative of an urban Australian population. Finally, 327 
the correlations between anthropometric/biochemical parameters and adipose hormones or 328 
markers of insulin sensitivity do not necessarily indicate the existence of a causal 329 
relationship. Thus, further intervention studies are necessary to investigate the extent of the 330 
clinical implications associated with these findings. 331 
Insulin resistance and the subsequent development of T2DM remain primarily lifestyle 332 
disorders. With correlations to liver function and plasma phospholipid fatty acid 333 
concentrations it would follow that these parameters may serve as markers for identifying 334 
overweight and obese individuals at a greater risk of developing insulin resistance as well as 335 
potential therapeutic targets though further randomised clinical trials are needed. 336 
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